RAIN-32 Posters and Presentations
AACR-NCI-EORTC 2021MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan
Vijaya Tirunagaru, Ph.D.
IASLC 2021 World Conference on Lung Cancer
The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma
Lynn Heasley, Ph.D.
A Phase 1 Dose-Escalation Study of Milademetan in Combination With 5-Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Courtney D. DiNardo
RAD52 Research Program Publications
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
Nucleic Acids Res. 2016 May 19;44(9):4189-99